Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs

被引:234
作者
Dale, Elena [1 ]
Bang-Andersen, Benny [2 ]
Sanchez, Connie [1 ]
机构
[1] Lundbeck Res USA, Paramus, NJ 07652 USA
[2] Lundbeck Res DK, DK-2500 Valby, Denmark
关键词
Depression; Antidepressants; Serotonin; Glutamate; SSRI; VORTIOXETINE LU AA21004; NK1 RECEPTOR ANTAGONIST; D-ASPARTATE ANTAGONIST; CORTICOTROPIN-RELEASING HORMONE; ANTIDEPRESSANT-LIKE ACTIVITY; DOUBLE-BLIND; MAJOR DEPRESSION; SEROTONIN REUPTAKE; NMDA RECEPTOR; MULTIMODAL ANTIDEPRESSANT;
D O I
10.1016/j.bcp.2015.03.011
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
The monoamine hypothesis has been the prevailing hypothesis of depression over the last several decades. It states that depression is associated with reduced monoamine function. Hence efforts to increase monoamine transmission by inhibiting serotonin (5-HT) and norepinephrine (NE) transporters has been a central theme in depression research since the 1960s. The selective 5-HT reuptake inhibitors (SSR1s) and 5-HT and NE reuptake inhibitors (SNRIs) that have emerged from this line of research are currently first line treatment options for major depressive disorder (MOD). One of the recent trends in antidepressant research has been to refine monoaminergic mechanisms by targeting monoaminergic receptors and additional transporters (e.g. with multimodal drugs and triple re-uptake inhibitors) or by adding atypical antipsychotics to SSR1 or SNRI treatment. In addition, several other hypotheses of depression have been brought forward in pre-clinical and clinical research based on biological hallmarks of the disease and efficacy of pharmacological interventions. A central strategy has been to target glutamate receptors (for example, with intravenous infusions of the N-methyl-c-aspartate (NMDA) receptor antagonist ketamine). Other strategies have been based on modulation of cholinergic and gamma-aminobutyric acid (GABA)ergic transmission, neuronal plasticity, stress/hypothalamic pituitary adrenal(HPA)-axis, the reward system and neuroinflammation. Here we review the pharmacological profiles of compounds that derived from these strategies and have been recently tested in clinical trials with published results. In addition, we discuss putative treatments for depression that are being investigated at the preclinical level and outline future directions for antidepressant research. (C) 2015 The Authors. Published by Elsevier Inc.
引用
收藏
页码:81 / 97
页数:17
相关论文
共 201 条
[1]
Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study [J].
Abbasi, Seyed-Hesameddin ;
Hosseini, Fahimeh ;
Modabbernia, Amirhossein ;
Ashrafi, Mandana ;
Akhondzadeh, Shahin .
JOURNAL OF AFFECTIVE DISORDERS, 2012, 141 (2-3) :308-314
[2]
CLINICAL TRIAL OF ADJUNCTIVE CELECOXIB TREATMENT IN PATIENTS WITH MAJOR DEPRESSION: A DOUBLE BLIND AND PLACEBO CONTROLLED TRIAL [J].
Akhondzadeh, Shahin ;
Jafari, Sara ;
Raisi, Firoozeh ;
Nasehi, Abbas Ali ;
Ghoreishi, Aboulfazl ;
Salehi, Bahman ;
Mohebbi-Rasa, Soodeh ;
Raznahan, Maedeh ;
Kamalipour, Abbas .
DEPRESSION AND ANXIETY, 2009, 26 (07) :607-611
[3]
Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study [J].
Alam, Mohammed Y. ;
Jacobsen, Paula L. ;
Chen, Yinzhong ;
Serenko, Michael ;
Mahableshwarkar, Atul R. .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (01) :36-44
[4]
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder [J].
Alvarez, Enric ;
Perez, Victor ;
Dragheim, Marianne ;
Loft, Henrik ;
Artigas, Francesc .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 (05) :589-600
[5]
Rates of 5 Common Antidepressant Side Effects Among New Adult and Adolescent Cases of Depression: A Retrospective US Claims Study [J].
Anderson, Heather D. ;
Pace, Wilson D. ;
Libby, Anne M. ;
West, David R. ;
Valuck, Robert J. .
CLINICAL THERAPEUTICS, 2012, 34 (01) :113-123
[6]
[Anonymous], 2009, Summary of product characteristics: Xolair
[7]
[Anonymous], 2013, BEHAV NEUROSCI
[8]
[Anonymous], MAJ DEPR DIS 53 ANN
[9]
[Anonymous], 2014, INT J NEUROPSYCHOPHA
[10]
Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects [J].
Areberg, Johan ;
Luntang-Jensen, Michael ;
Sogaard, Birgitte ;
Nilausen, Dorrit O. .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 110 (04) :401-404